Medicago has rapidly developed vaccine candidates for RNA viruses previously, including a research-grade influenza vaccine in 2009. That research led to its 2019 submission of a commercializable quadrivalent influenza vaccine to Health Canada. Medicago's technology utilizes plants to produce viruslike particles that mimic viral shape and dimensions to trigger an immune response. Medicago is not the first to develop a candidate vaccine, as China and the NIH began clinical trials, but in a globalized world with inevitable and evolving diseases, companies with rapid development capabilities like Medicago have the chance to demonstrate value. Clients should aggressively pursue such developers for solutions within and outside of human health.
For the original news article,